Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11627432 | 0.88 | RAB9A (0.54) | NPC1RAB9AENPP2POLBPTPN1 | |
| SCHEMBL9588889 | 0.86 | NPC1 (0.70) | NPC1RAB9APOLBCASP3PTPN1 | |
| SCHEMBL15516309 | 0.86 | NPC1 (0.66) | NPC1RAB9AENPP2POLBCASP3 | |
| SCHEMBL8705480 | 0.85 | NPC1 (0.61) | NPC1RAB9AENPP2POLBCASP3 | |
| SCHEMBL4291027 | 0.85 | NPC1 (0.64) | NPC1RAB9AENPP2POLBCASP3 | |
| SCHEMBL2559038 | 0.82 | NPC1 (0.61) | NPC1RAB9AENPP2POLBCASP3 | |
| SCHEMBL8606033 | 0.82 | TACR3 (0.56) | NPC1RAB9AENPP2POLBPTPN1 | |
| SCHEMBL9315291 | 0.82 | NPC1 (0.53) | NPC1RAB9AENPP2POLBCASP3 | |
| SCHEMBL6923337 | 0.81 | NPC1 (0.59) | NPC1RAB9AENPP2POLBCASP3 | |
| SCHEMBL27608697 | 0.81 | ENPP2 (0.65) | NPC1RAB9AENPP2PTPN1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964730-B2 | Amino-substituted ethylamino β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| WO-2011016576-A1 | ALANINE DERIVATIVES AS INHIBITORS OF APOPTOSIS PROTEINS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | WO | disclosed |
| US-20090111850-A1 | Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20090036525-A1 | Non-Natural Amino Acid Derivatives | POXIMAGEN LTD. (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-1981839-A1 | NON-NATURAL AMINO ACID DERIVATIVES | Proximagen Ltd. (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007091018-A1 | NON-NATURAL AMINO ACID DERIVATIVES | PROXIMAGEN LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-4829080-A | SKIN DISORDERS, PSORIASIS, ACNE | L'OREAL (FR) | 1989-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036525-A1 | Non-Natural Amino Acid Derivatives | CHRNA6, PARK7, CHRNA7 | NPC1 3699/4885RAB9A 1181/4885ENPP2 908/4885 |
| US-20090111850-A1 | Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2A | NPC1 1635/4885RAB9A 1802/4885ENPP2 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.